Phase 1 Dose Escalation Study of ONO-4578 Given as Monotherapy and Combinations of ONO-4578 and ONO-4538 in Subjects Advanced or Metastatic Solid Tumors

Trial Profile

Phase 1 Dose Escalation Study of ONO-4578 Given as Monotherapy and Combinations of ONO-4578 and ONO-4538 in Subjects Advanced or Metastatic Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 24 May 2017

At a glance

  • Drugs ONO 4578 (Primary) ; Nivolumab; Nivolumab; ONO 4578
  • Indications Solid tumours
  • Focus Adverse reactions; Biomarker
  • Sponsors Ono Pharmaceutical
  • Most Recent Events

    • 10 Apr 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top